Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.

Literature DB >> 24487414

Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.

Abstract

Inhibitor of Apoptosis (IAP) proteins exert essential functions during tumorigenesis as well as treatment resistance by simultaneously blocking cell death pathways and promoting cell survival. As IAP proteins are typically aberrantly expressed in human cancers including hematological malignancies, they represent in principle promising targets for therapeutic interventions. There are currently exciting opportunities to rationally exploit the therapeutic targeting of IAP proteins for the treatment of leukemia and lymphoma. Further insights into the signaling pathways that are under the control of IAP proteins and into the specific IAP protein-dependent vulnerabilities of hematological neoplasms are expected to pave the avenue to novel treatment strategies.

Entities: Disease Species

Mesh：

Substances：

Year: 2014 PMID： 24487414 DOI： 10.1038/leu.2014.56

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

100 in total

1. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.

Authors: Haiying Sun; Zaneta Nikolovska-Coleska; Jianfeng Lu; Jennifer L Meagher; Chao-Yie Yang; Su Qiu; York Tomita; Yumi Ueda; Sheng Jiang; Krzysztof Krajewski; Peter P Roller; Jeanne A Stuckey; Shaomeng Wang
Journal: J Am Chem Soc Date: 2007-11-14 Impact factor: 15.419

2. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib.

Authors: Hugo Seca; Raquel T Lima; José E Guimarães; M Helena Vasconcelos
Journal: Hematology Date: 2011-03 Impact factor: 2.269

3. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.

Authors: I Tamm; S M Kornblau; H Segall; S Krajewski; K Welsh; S Kitada; D A Scudiero; G Tudor; Y H Qui; A Monks; M Andreeff; J C Reed
Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531

4. xIAP induces cell-cycle arrest and activates nuclear factor-kappaB : new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells.

Authors: B Levkau; K J Garton; N Ferri; K Kloke; J R Nofer; H A Baba; E W Raines; G Breithardt
Journal: Circ Res Date: 2001-02-16 Impact factor: 17.367

5. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.

Authors: Domagoj Vucic; Matthew C Franklin; Heidi J A Wallweber; Kanad Das; Brendan P Eckelman; Hwain Shin; Linda O Elliott; Saloumeh Kadkhodayan; Kurt Deshayes; Guy S Salvesen; Wayne J Fairbrother
Journal: Biochem J Date: 2005-01-01 Impact factor: 3.857

6. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

Authors: B Z Carter; M Milella; T Tsao; T McQueen; W D Schober; W Hu; N M Dean; L Steelman; J A McCubrey; M Andreeff
Journal: Leukemia Date: 2003-11 Impact factor: 11.528

Review 7. Survivin, cancer networks and pathway-directed drug discovery.

Authors: Dario C Altieri
Journal: Nat Rev Cancer Date: 2008-01 Impact factor: 60.716

8. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors: Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal: Cancer Cell Date: 2007-08 Impact factor: 31.743

Review 9. Cell death in health and disease.

Authors: Richard A Lockshin; Zahra Zakeri
Journal: J Cell Mol Med Date: 2007-11-20 Impact factor: 5.310

10. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.

Authors: Brian J Zarnegar; Yaya Wang; Douglas J Mahoney; Paul W Dempsey; Herman H Cheung; Jeannie He; Travis Shiba; Xiaolu Yang; Wen-Chen Yeh; Tak W Mak; Robert G Korneluk; Genhong Cheng
Journal: Nat Immunol Date: 2008-11-09 Impact factor: 25.606

26 in total

1. Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death.

Authors: H Schoeneberger; K Belz; B Schenk; S Fulda
Journal: Oncogene Date: 2014-11-10 Impact factor: 9.867

Review 2. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.

Authors: Brian Ball; Amer Zeidan; Steven D Gore; Thomas Prebet
Journal: Leuk Lymphoma Date: 2016-09-21

Review 3. Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors: M Pizzi; M Boi; F Bertoni; G Inghirami
Journal: Leukemia Date: 2016-06-08 Impact factor: 11.528

4. The role of NF-κB and Smac/DIABLO proteins in the treatment response and survival of acute myeloid leukemia patients.

Authors: Agnieszka Pluta; Tadeusz Robak; Barbara Cebula; Agata Majchrzak; Piotr Pluta; Kamil Brzozowski; Konrad Stępka; Anna Szmigielska-Kapłon; Olga Grzybowska-Izydorczyk; Magdalena Czemerska; Piotr Smolewski; Agnieszka Wierzbowska
Journal: Arch Med Sci Date: 2019-11-19 Impact factor: 3.318

Review 5. Caspases: therapeutic targets in neurologic disease.

Authors: Carol M Troy; Ying Y Jean
Journal: Neurotherapeutics Date: 2015-01 Impact factor: 6.088

6. Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer.

Authors: Tingting Hu; Shuqiang Weng; Wenqing Tang; Ruyi Xue; She Chen; Guoxiang Cai; Yu Cai; Xizhong Shen; Si Zhang; Ling Dong
Journal: PLoS One Date: 2015-05-01 Impact factor: 3.240

7. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.

Authors: Charlotte Fristedt Duvefelt; Susanne Lub; Prasoon Agarwal; Linda Arngården; Anna Hammarberg; Ken Maes; Els Van Valckenborgh; Karin Vanderkerken; Helena Jernberg Wiklund
Journal: Oncotarget Date: 2015-08-21

Review 8. Novel strategies to target the ubiquitin proteasome system in multiple myeloma.

Authors: Susanne Lub; Ken Maes; Eline Menu; Elke De Bruyne; Karin Vanderkerken; Els Van Valckenborgh
Journal: Oncotarget Date: 2016-02-09

9. Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.

Authors: J Xin; D You; P Breslin; J Li; J Zhang; W Wei; J Cannova; A Volk; R Gutierrez; Y Xiao; A Ni; G Ng; R Schmidt; Z Xia; J Pan; H Chen; M M Patel; P C Kuo; S Nand; A R Kini; J Zhang; J Chen; J Zhu; J Zhang
Journal: Leukemia Date: 2016-10-17 Impact factor: 11.528

10. Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia.

Authors: M Schirmer; L Trentin; M Queudeville; F Seyfried; S Demir; E Tausch; S Stilgenbauer; S M Eckhoff; L H Meyer; K-M Debatin
Journal: Cell Death Dis Date: 2016-01-14 Impact factor: 8.469